Since GCs have historically been the only medications used in CAH to manage an excess of adrenocorticotropic hormone (ACTH) and adrenal androgens, as well as replace cortisol, there is considerable unmet need in this patient population, particularly for patients who have burdensome GC dose-related adverse effects (13). This evidence concerns the gene POMC and congenital adrenal hyperplasia.